What Dyscovry Science does

Dyscovry Science is a Toronto, Canada-based for-profit biotechnology company whose stated focus is the biosynthetic manufacturing of psilocybin and its derivatives. The company is privately held and operates from a single identified location in Toronto. Its functional positioning — biosynthetic production rather than extraction or chemical synthesis — implies a synthetic biology approach that uses engineered biological systems (e.g., microbial fermentation) to produce psilocybin and derivative molecules at scale, an approach that has been adopted across the broader psychedelic therapeutics supply chain to address scalability, purity, and cost limitations of traditional extraction methods.

The company's product portfolio, specific pipeline candidates, manufacturing capacity, regulatory licenses (e.g., Health Canada's Controlled Drugs and Substances Act authorizations, GMP status), and go-to-market model are not documented in the available source material. There is no disclosed information on whether the company operates as a B2B contract manufacturer supplying active pharmaceutical ingredients (API) to clinical developers and research institutions, sells proprietary compounds, or pursues internal drug development. No customers, distribution channels, pricing, revenue model, headcount, funding history, management team, or strategic partnerships are recorded.

Based on the limited evidence available, Dyscovry Science appears to be an early-stage, privately funded Canadian biotech in the psychedelic API manufacturing segment. The investment-relevant unknowns include capital intensity of biosynthetic scale-up, regulatory pathway to commercial manufacturing, intellectual property position (no patents disclosed), competitive positioning versus other psilocybin API producers (e.g., Compass Pathways' suppliers, Filament Health, Psygen Labs), and the durability of any first-mover or cost advantages in this niche.

Name

Dyscovry Science

Website

https://dyscovry.com

Company type

Private

Operating status

Operating

Short description

Dyscovry Science is a Toronto-based private biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives for the psychedelic pharmaceutical supply chain.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biosynthetic manufacturing
• Psilocybin derivatives
• Psychedelic pharmaceuticals
• Biotechnology manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Dyscovry Science is a Toronto-based biotechnology company that focuses on the biosynthetic manufacturing of psilocybin and its derivatives. The company applies biological production methods to manufacture psychedelic active pharmaceutical ingredients intended for use in therapeutic and research applications.

Product overview

Dyscovry Science is a technology company. No detailed product information, portfolio structure, or named offerings were available in the source content.

Differentiator

Problem solved

Functional benefit

Products and services

• Psilocybin and psilocybin derivatives

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• GH Research: GH Research is a clinical-stage biopharmaceutical company developing psychedelic therapies including psilocybin-based treatments. It is comparable as a psilocybin-focused therapeutics developer with potential demand for manufactured psilocybin API.
• Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression and operates one of the most advanced psilocybin clinical programs. It is directly comparable as a leading psilocybin-focused therapeutics company and a likely downstream customer or competitor for psilocybin API supply.
• Cybin Inc. Cybin is a psychedelic therapeutics company developing proprietary psilocybin and deuterated psilocybin analogs for mental health conditions. It is comparable as a psilocybin-derivative-focused developer and a potential customer or collaborator for novel psilocybin derivatives.
• Filament Health: Filament Health is a naturally-derived psychedelic drug developer and manufacturer with regulatory authorization for psilocybin production. It is directly comparable as a psilocybin-focused drug substance manufacturer, although using natural extraction rather than biosynthesis.
• MindMed: MindMed is a psychedelic therapeutics company developing LSD- and psilocybin-based treatments for mental health conditions. It is comparable as a peer in psychedelic drug development with overlapping supply chain needs for psilocybin.

Emerging players

• Mydecine Innovations Group: Mydecine Innovations Group is a psychedelic medicine company developing psilocybin and other psychedelic-based therapies. It is comparable as an emerging peer operating in the psychedelic drug development space with overlapping molecule focus.
• Beckley Psytech: Beckley Psytech is a clinical-stage psychedelic medicine company developing psilocybin and other psychedelic-based therapies. It is comparable as an emerging peer in psychedelic drug development with similar downstream API supply needs.

Broad incumbents

• Atai Life Sciences: Atai Life Sciences is a clinical-stage biopharmaceutical company with a broad platform of psychedelic and non-psychedelic mental health therapies. It is comparable as a well-capitalized incumbent in the psychedelic drug development space with substantially more resources.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dyscovry Science